Clinical Trial Update: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease [Phase 1]

View source ↗

Summary

Phase 1 trial results for obinutuzumab in Chinese participants with CD20+ malignant disease. Diseases studied include chronic lymphocytic leukemia, diffuse larg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2016-04-25